In lung adenocarcinoma, previous studies found that the expression of PCMT1 was significantly higher in patients with clinically advanced or invasive adenocarcinoma than in patients with clinically early or preinvasive adenocarcinoma (Zhao et al., 2012). Here, PCMT1 is linked to lung adenocarcinoma.